Sign in to view content

Intermittent to Continuous Therapy for Diabetic Macular Edema leads to Reduction in Treatment Frequency and Reduced Retinal Thickness Fluctuations

Seenu M. Hariprasad, MD

Video
Published 2019

Related

Masked Safety Data from ZETA-1, an Ongoing 24-Week Phase 2 Clinical Trial of APX3330, an Oral Therapeutic Being Developed for the Treatment of Diabetic Retinopathy
Michael J Allingham, MD, PhD
Annual Meeting Talks
2022
Canadian Treat-and-Extend Analysis Trial with Ranibizumab in Patients With Neovascular AMD: CANTREAT Study 1-Year Results
Peter J. Kertes, MD, FRCS(C)
Updates from the Field
2018
Comparative Efficacy of Different Anti-VEGF Treatment Regimens in Patients With nAMD: A Network Meta-Analysis
Diana V Do, MD, FASRS
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more